Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer

Completed · Phase 1

Conditions studied: Breast Cancer

In brief

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen or LY353381 may fight breast cancer by blocking the use of estrogen. PURPOSE: This randomized phase I trial is studying how well tamoxifen works on the biomarkers of the tumor tissue, compared with LY353381, in treating women with newly diagnosed breast cancer.

Key facts

Study ID

NCT00005886

Run by

University of Kansas Medical Center

Starts

2000-07-01

Expected to finish

2002-08-01

Last updated by the study team

2017-01-13

Who can join

Age: 18 and older, up to 120. Sex: female. Healthy volunteers: not accepted.

Where it is running

• University of Alabama at Birmingham Comprehensive Cancer Center — Birmingham, Alabama, United States
• Jonsson Comprehensive Cancer Center, UCLA — Los Angeles, California, United States
• Comprehensive Cancer Centers of the Desert — Palm Springs, California, United States
• Loyola University Medical Center — Maywood, Illinois, United States
• University of Kansas Medical Center — Kansas City, Kansas, United States
• Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio, United States
• Arthur G. James Cancer Hospital - Ohio State University — Columbus, Ohio, United States
• Kimmel Cancer Center of Thomas Jefferson University - Philadelphia — Philadelphia, Pennsylvania, United States
• U.S. Oncology Research Inc. — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.